Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629342 | 0.77 | CHRM2 (0.50) | LMNATAAR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL6077476 | 0.76 | IDO1 (0.48) | KMT2AMEN1IDO1ALDH1A1HPGD | |
| SCHEMBL20905599 | 0.76 | SCN8A (0.49) | LMNATAAR1L3MBTL1KMT2AMEN1 | |
| SCHEMBL6819 | 0.76 | TAAR1 (0.63) | LMNATAAR1L3MBTL1KMT2AMEN1 | |
| SCHEMBL31488449 | 0.75 | NPC1 (0.50) | LMNATAAR1L3MBTL1KMT2AMEN1 | |
| SCHEMBL11195571 | 0.75 | NPC1 (0.50) | LMNATAAR1L3MBTL1KMT2AMEN1 | |
| SCHEMBL6071681 | 0.75 | MPO (0.60) | LMNATAAR1L3MBTL1KMT2AMEN1 | |
| SCHEMBL3866918 | 0.73 | L3MBTL1 (0.66) | L3MBTL1KMT2AMCL1ALDH1A1KDM4E | |
| SCHEMBL631227 | 0.72 | MPO (0.58) | LMNATAAR1L3MBTL1KMT2AMEN1 | |
| SCHEMBL18405086 | 0.72 | TAAR1 (0.53) | LMNATAAR1L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240023549-A1 | FUNGICIDAL ARYL AMIDINES | CORTEVA AGRISCIENCE LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240023549-A1 | FUNGICIDAL ARYL AMIDINES | CORTEVA AGRISCIENCE LLC (US) | 2024-01-25 | — | — | US | disclosed |
| CN-116529235-A | Fungicidal aryl amidines | 科迪华农业科技有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022109362-A1 | FUNGICIDAL ARYL AMIDINES | CORTEVA AGRISCIENCE LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| CN-1617849-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-05-18 | — | — | CN | disclosed |
| EP-1467695-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003049690-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | LMNA 3521/4885TAAR1 4746/4885L3MBTL1 2246/4885 |
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | LMNA 2590/4885TAAR1 3904/4885L3MBTL1 480/4885 |
| US-20240023549-A1 | FUNGICIDAL ARYL AMIDINES | CYP1A1, CYP1A2, CYP1B1 | LMNA 3813/4885TAAR1 676/4885L3MBTL1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.